Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876871 | 1.00 | NOTUM (0.51) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL6851980 | 0.82 | NOTUM (0.58) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL6854287 | 0.79 | NOTUM (0.55) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL17694561 | 0.78 | NOTUM (0.78) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL6852297 | 0.75 | NOTUM (0.50) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL6852304 | 0.75 | NOTUM (0.50) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL2610163 | 0.75 | NOTUM (0.75) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL27920486 | 0.75 | NOTUM (0.58) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL6852556 | 0.72 | NOTUM (0.55) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL8505384 | 0.71 | TP53 (0.50) | NOTUMALDH1A1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | NOTUM 2862/4885ALDH1A1 2109/4885KDM4E 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.